Clinical Context
A typical patient is an adult presenting for pharmacologic prophylaxis against venous thromboembolism (VTE) or treatment of acute deep vein thrombosis when fondaparinux dosing of 0.5 mg is appropriate (for example, as a pediatric or specialized low-dose clinical scenario). The workflow begins with a clinician order for J1652 (fondaparinux sodium, 0.5 mg) documented in the medical record with indication, weight-based dosing rationale, and informed consent when required. A licensed nurse or pharmacist prepares the subcutaneous injection using facility or outpatient pharmacy supply. Prior to administration, the provider verifies the patient identity, allergy history, recent coagulation studies if indicated, and concurrent anticoagulant or antiplatelet therapy. The injection is administered subcutaneously in the abdomen, thigh, or upper arm, with observation for immediate adverse reactions per facility protocol. Documentation includes the J1652 HCPCS code, lot number, expiration date, route (subcutaneous), site of administration, clinician or injector taxonomy, and any applicable modifier(s) reflecting circumstances such as service distinctness, drug wastage, or patient status. Billing follows payer-specific rules for drug administration, reporting the drug HCPCS plus any applicable administration CPT if required by the payor policy. Common clinical settings include inpatient wards, emergency departments, ambulatory infusion clinics, outpatient procedure areas, and specialty pediatric clinics when low-dose fondaparinux is indicated.